Research Type: Extramural
In this project Professor Fazekas and team will analyse pre- and post-therapy blood samples from breast cancer patients and use machine learning statistical techniques to identify the immune signatures that can predict patient response to a particular therapy with the greatest accuracy.
Dr van Delft and Dr Lew co-lead a team with Dr White that aims to enhance the effectiveness of venetoclax, rendering resistant cancer cells sensitive to treatment.
The project aims to develop experimental research using the proposed hardware to show 3D imagining during treatment, MRI quality imaging during treatment and reconstructing actual delivered dose post treatment.
If successful, this project will generate clinically translatable approaches to enhance AML therapy ready for progression to clinical trials to improve outcomes for AML patients.
Professor Turner’s team aims to use cutting edge imaging approaches to shed light on how changes in nutrient metabolism and intracellular signalling contribute to two lethal characteristics of pancreatic cancer, namely chemoresistance and metastatic spread.
Dr Mithraprabhu and her team aims to overcome the challenges caused by the genetic complexity of multiple myeloma by using DNA obtained from the blood instead of a single-site bone marrow biopsy.
The team has developed a methodology to map the fibrotic tumour landscape, through real-time imaging of (i) the proximity of cancer cells to the host blood supply, (ii) their location with regards to the tumour invasive borders and (iii) the surrounding tissue compartment.
Associate Professor MacKenzie and her team will define specific drug targets and develop diagnostic methods for therapeutic application in cancers that relay on a specific telomere maintenance mechanism referred to as Alternative Lengthening of Telomeres (ALT).
Dr Jenny Wang and her team have discovered a key self-renewal pathway essential for the survival of leukaemia-initiating cells.
Dr Latham’s team is pursuing the preclinical assessment and development of a novel class of drugs that aim to prevent cancer relapse by inhibiting the growth of cells that have already metastasised.